Abstract: The invention relates to a new neurotensin analogue, or a salt thereof, useful for targeting to neurotensin receptor-positive tumors, like ductal pancreatic adenocarcinoma, exocrine pancreatic cancer, invasive ductal breast cancers, colon adenocarcinoma, small cell lung carcinoma, Ewing sarcoma, meningioma, medulloblastoma and astrocytoma.

Abstract: The invention relates to a new neurotensin analogue, or a salt thereof, useful for targeting to neurotensin receptor-positive tumors, like ductal pancreatic adenocarcinoma, exocrine pancreatic cancer, invasive ductal breast cancers, colon adeno-carcinoma, small cell lung carcinoma, Ewing sarcoma, meningioma, medulloblastoma and astrocytoma.

Abstract: A method for the assay of the circulating extracellular portion of the IRAP protein (“insulin responsive aminopeptidase”) includes at least one stage of quantitative assay of the purified, secreted, extracellular portion of IRAP, via at least one labelled peptide, the labelled peptide interacting specifically with the extracellular portion of IRAP.

Abstract: The present invention relates to the use of an angiotensin IV antagonist that decreases the effects on angiotensinogen expression of angiotensin IV in vascular smooth muscle cells for preparing a drug to treat or prevent type II diabetes, insulin resistance or cardiovascular risk related to metabolic syndrome, as well as to pharmaceutical compositions comprising one such antagonist.

Abstract: The invention relates to a labelled peptide compound, wherein the peptide has a selective neurotensin receptor affinity and is represented by the general formula R1—(1Pro)n—2Xaa—3Xbb—4Xcc—5Xdd—6Xee—7Leu—OH(SEQ ID NO.2)  (I) wherein: R1 is a (C1-C3)alkanoyl group, an arylcarbonyl group, an aryl-(C1-C3)alkanoyl group, or a chelating group attached by an amide bond or through a spacing group to the peptide molecule; Xaa and Xbb are each individually Arg or Lys; Xcc is an unsubstituted or substituted cyclic amino acid, preferably selected from Pro and Hyp; Xdd is Tyr, Trp or Phe; Xee is Leu, Ile or t.

Abstract: The invention relates to a labelled peptide compound, wherein the peptide has a selective neurotensin receptor affinity and is represented by the general formulaR.sub.1 -(.sup.1 Pro).sub.n -.sup.2 Xaa-.sup.3 Xbb-.sup.4 Xcc-.sup.5 Xdd-.sup.6 Xee-.sup.7 Leu-OH (SEQ ID NO:2) (I)wherein:R.sub.1 is a (C.sub.1 -C.sub.3)alkanoyl group, an arylcarbonyl group, an aryl-(C.sub.1 -C.sub.3)alkanoyl group, or a chelating group attached by an amide bond or through a spacing group to the peptide molecule;Xaa and Xbb are each individually Arg or Lys;Xcc is an unsubstituted or substituted cyclic amino acid, preferably selected from Pro and Hyp;Xdd is Tyr, Trp or Phe;Xee is Leu, Ile or t.-butylalanine; andn is 0 or 1;and wherein said peptide is labelled with (a) a metal isotope, or (b) with a radioactive halogen isotope; on the understanding that:(i) if the label is a metal isotope, R.sub.